Revelation Biosciences Taps Top Scientists Julia Bohannon and Antonio Hernandez to Join Advisory Board

Revelation Biosciences Inc. (NASDAQ: REVB) is thrilled to announce the addition of two esteemed scientists, Julia Bohannon, Ph.D. and Antonio Hernandez, M.D., to its scientific advisory board. Both inventors of the cutting-edge phosphorylated hexaacyl disaccharide (PHAD) technology, licensed from Vanderbilt University, these experts are sure to prove invaluable to the Company’s mission of developing immunologic-based therapies for the prevention and treatment of disease.

Dr. Julia Bohannon is an Associate Professor in the Department of Anesthesiology and the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center. Through her research program, funded by the NIH, she focuses on the development of immunomodulatory treatments to enhance innate immune responses after severe burn injury in order to prevent nosocomial infections – the leading cause of death in burn patients. Dr. Bohannon’s research investigates the ways in which critical illness affects the immune system and increases vulnerability to infection, with the ultimate goal of creating effective methods to reduce morbidity and mortality in critically injured individuals.

Dr. Bohannon is a renowned expert in the field of burn immunology, having been honored with numerous awards for her research excellence. After obtaining her bachelor’s degree in molecular biology at Eastern Kentucky University, she went on to earn her Ph.D. in biomedical sciences from the University of Texas Medical Branch. She then completed her postdoctoral training at Vanderbilt University Medical Center Department of Anesthesiology, where she was awarded the Vanderbilt University Medical Center Faculty Clinical and Translational Research Scholar’s Award, the G. Jeanette Thorbecke Award from the Society of Leukocyte Biology, and a Maximizing Investigator’s Research Award from the National Institute of General Medicine. With this award, she is currently funded for her studies in the field of burn immunology.

Dr. Antonio Hernandez is a renowned expert in the fields of Anesthesiology Critical Care Medicine, Cardiothoracic Anesthesiology, and Research at Vanderbilt University Medical Center. Combining his knowledge and experience, Dr. Hernandez has developed innovative therapies such as synthetic de novo vaccine adjuvants to enhance innate immunity and protect against inflammation-induced organ injury. By employing clinically relevant models, he is working to train the innate immune system to improve antimicrobial function and reduce organ injury in acute sepsis and sepsis-induced immunosuppression cases. As Co-Medical Director of the CV-ICU, Dr. Hernandez is dedicated to improving outcomes in critically ill and cardiac surgery patients through his groundbreaking research and discoveries.

Dr. Hernandez is an esteemed anesthesiologist and cardiothoracic specialist who has dedicated his career to advancing critical care services and improving the lives of his patients. After obtaining his Bachelor of Science in Biology with honors from the University of Texas at El Paso and his Medical Doctorate from the University of Texas Medical Branch at Galveston, he completed an anesthesiology residency and fellowships in Anesthesiology Critical Care Medicine and Cardiothoracic Anesthesiology. Dr. Hernandez then pursued his Master of Science in Clinical Investigation at Vanderbilt University and was appointed to the faculty. Under his leadership, the cardiovascular intensive care unit has become the world’s largest heart transplant program for three consecutive years, and he has developed comprehensive perioperative support services for advanced care programs, including total artificial heart, pulmonary endarterectomy, combined heart-lung, and heart-liver transplantation, as well as various mechanical support services such as extracorporeal membrane oxygenation (ECMO).

I’m thrilled to join Revelation’s Scientific Advisory Board and to be able to lend my expertise to the team. The Company has generated compelling data on PHAD, and I’m looking forward to working with the scientific team and helping guide them in developing PHAD’s potential to treat or prevent infections. It’s an exciting prospect and I’m eager to get started!

Dr. Hernandez is eager to join the dedicated and driven team at Revelation Biosciences to develop and shape new approaches for the prevention and treatment of healthcare-associated bacterial infections. He believes that Revelation Biosciences is uniquely positioned to make a valuable contribution to reducing the duration and severity of healthcare associated infections, such as post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

We are thrilled and proud to announce the addition of two esteemed scientific experts—Dr. Hernandez and Dr. Bohannon—to our Scientific Advisory Board. Their expertise in augmenting the innate immune response to treat infection will be invaluable to Revelation’s mission of creating innovative therapies to address the medical needs that are currently unmet. We look forward to working with our Scientific Advisory Board and benefitting from their invaluable feedback and collaboration.

About Revelation Biosciences Inc.

Revelation Biosciences is revolutionizing the life sciences with its innovative immunologic-based therapies for the prevention and treatment of disease. REVTx‑100, REVTx‑300, REVTx‑200 and REVTx‑99b are just some of the products in development, all of which are based on the powerful biology of phosphorylated hexaacyl disaccharide (PHAD). From bacterial infection to acute and chronic organ disease, food allergies and more, Revelation is leading the way in cutting-edge treatments to help people lead healthier, happier lives.

Leave a Comment